Non! to Non-Steroidal Anti-Inflammatory Therapy for Inflammatory Lung Disease in Cystic Fibrosis (at Least at the Moment)

Journal of Pediatrics

Volumn 151, Issue 3, 2007, Pages 228-230

  Bush, Andrew ^a   Davies, Jane ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IBUPROFEN; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ANTIINFLAMMATORY ACTIVITY; BONE DISEASE; CHILD; CYSTIC FIBROSIS; DIABETES MELLITUS; EDITORIAL; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG DISEASE; LUNG FUNCTION; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CYSTIC FIBROSIS; HUMANS; IBUPROFEN; PREDNISONE;

EID: 34548023098     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2007.06.019     Document Type: Editorial

References (27)

1. Borza D.B., Neilson E.G., and Hudson B.G. Pathogenesis of Goodpasture syndrome: a molecular perspective. Semin Nephrol 23 (2003) 522-531
2. Konstan M.W., and Berger M. Infection and inflammation of the lungs in cystic fibrosis. In: Davis P.B. (Ed). Cystic fibrosis (1993), Marcel Dekker, New York 219-276
3. Auerbach H.S., Williams M., Kirkpatrick J.A., and Colten H.R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 2 (1985) 686-688
4. Eigen H., Rosenstein B.J., FitzSimmons S., and Schidlow D.V. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 126 (1995) 515-523
5. Dezateux C., Walters S., and Balfour-Lynn I. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2 (2000) CD001915
6. Balfour-Lynn I.M., Lees B., Hall P., Phillips G., Khan M., Flather M., et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 173 (2006) 1356-1362
7. Solomon M.P., Wilson D.C., Corey M., Kalnins D., Zielenski J., Tsui L.C., et al. Glucose intolerance in children with cystic fibrosis. J Pediatr 142 (2003) 128-132
8. Elkin S.L., Vedi S., Bord S., Garrahan N.J., Hodson M.E., and Compston J.E. Histomorphometric analysis of bone biopsies from the iliac crest of adults with cystic fibrosis. Am J Respir Crit Care Med 166 (2002) 1470-1474
9. Stevens D.A., Moss R.B., Kurup V.P., Knutsen A.P., Greenberger P., Judson M.A., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 37 Suppl 3 (2003) S225-S264
10. 4 receptor antagonist) for the treatment of CF lung disease. Pediatr Pulmonol Suppl 28 (2005) 125-126
11. Lands L.C., Milner R., Cantin A.M., Manson M., and Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 151 (2007) 249-254
12. Konstan M.W., Byard P.J., Hoppel C.L., and Davis P.B. Effect of high dose ibuprofen in patients with cystic fibrosis. N Engl J Med 322 (1995) 848-854
13. Balfour-Lynn I.M., and Dezateux C. Corticosteroids and ibuprofen in cystic fibrosis. Thorax 54 (1999) 657
14. Kovesi T.A., Swartz R., and MacDonald N. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. N Engl J Med 338 (1998) 65-66
15. Scott C.S., Retsch-Bogart G.Z., and Henry M.M. Renal failure and vestibular toxicity in an adolescent receiving gentamicin and standard-dose ibuprofen. Pediatr Pulmonol 31 (2001) 314-316
16. Rinaldo J.E., and Pennock B. Effects of ibuprofen on endotoxin-induced alveolitis: biphasic dose response and dissociation between inflammation and hypoxemia. Am J Med Sci 291 (1986) 29-38
17. Merkus P.J., Tiddens H.A., and de Jongste J.C. Annual lung function changes in young patients with chronic lung disease. Eur Respir J 19 (2002) 886-891
18. Merkus P.J., Govaere E.S., Hop W.C., Stam H., Tiddens H.A., and de Jongste J.C. Preserved diffusion capacity in children with cystic fibrosis. Pediatr Pulmonol 37 (2004) 56-60
19. Que C., Cullinan P., and Geddes D. Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax 61 (2006) 155-157
20. Davis P.B., Byard P.J., and Konstan M.W. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 41 (1997) 161-165
21. Alton E.W., Davies J.C., and Geddes D.M. Biomarkers for cystic fibrosis: are we progressing?. Am J Respir Crit Care Med 175 (2007) 750-751
22. Green R.H., Brightling C.E., McKenna S., Hargadon B., Parker D., Bradding P., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002) 1715-1721
23. Pijnenburg M.W., Bakker E.M., Hop W.C., and De Jongste J.C. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 172 (2005) 831-836
24. Smith A.D., Cowan J.O., Brassett K.P., Herbison G.P., and Taylor D.R. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 352 (2005) 2163-2173
25. Zacharasiewicz A., Wilson N., Lex C., Erin E.M., Li A.M., Hansel T., et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med 171 (2005) 1077-1082
26. Pijnenburg M.W., Hofhuis W., Hop W.C., and De Jongste J.C. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 60 (2005) 215-218
27. Welch E.M., Barton E.R., Zhuo J., Tomizawa Y., Friesen W.J., and Trifillis P. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447 (2007) 87-91